News | February 05, 2022
Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore
Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021
Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019
The recommendations have been sent to the Drugs Controller General of India (DCGI) for the final approval
The company has reported standalone financial results for the period ended December 31, 2021.
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
The target demographic will be those between the ages of 30 and 65 years
Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use in more than 60 countries around the world
Unlike “Fast PCR” platforms - which uses LAMP/Isothermal technology and not gold standard RT-PCR - CoviSwift has high accuracy and sensitivity and is suitable for airports and hospitals
Subscribe To Our Newsletter & Stay Updated
